the time of relapse (Table 2) . Regardless, the presence of molecular heterogeneity among patients with trisomy-8-associated AML or MDS might explain the controversial prognostic influence of the specific cytogenetic abnormality. Finally, we show, for the first time, the occurrence of an IDH2 mutation in lymphoma and its disappearance with effective therapy; more studies are needed to validate our observation and clarify the pathogenetic or prognostic relevance of such an event.
The clinical course of chronic lymphocytic leukemia (CLL) is variable and depends on disease stage, prognostic factors, age and comorbidity. 1, 2 Complete remission (CR) or partial remissions are initially obtained in most fit patients treated with combinations of fludarabine (F), cyclophosphamide (C) and rituximab (R) (FC or FCR). 3 Unfortunately, all patients will eventually relapse. There is an unmet need for biological predictors of individual drug response to facilitate correct treatment decisions early on. So far, gene expression profiling (GEP) in vivo in CLL was mainly used in a cross-sectional approach by studying patient samples before treatment. 4 We applied a sequential GEP (sGEP) approach to investigate the gene expression signature of CD19 þ selected CLL cells before and after treatment in vivo. This was complemented by protein analysis as well as by functional in vitro analysis of selected targets. The goals of this study were to (1) define molecular signatures associated with good or poor response to treatment; (2) understand differences in gene expression profiles after treatment with rituximab with FC or FC alone; (3) define changes in expression signatures shortly after treatment in responding and resistant CLL cases; (4) identify novel targets to overcome resistance. A number of genes that were up-or downregulated in responding patients were identified. We also provide a list of genes that were upregulated in CLL cells in association with insufficient clinical response. This library may serve to design drug combinations or sequences of administration to avoid or overcome resistance. A total of 20 patients with CLL diagnosed by standard criteria were enrolled in this study between 2004 and 2007. Eight patients were recruited within the CLL-8 study of German CLL Study Group. Sixteen patients received first-line and four second-line treatment. All patients were in Binet stage B (N ¼ 10) or C (N ¼ 10). Characteristics of all study patients are given briefly in Table 1 and Supplementary Table 1 . Treatment was planned for six cycles with a 28-day interval according to standard FC or FCR protocols. 2, 3 Peripheral blood samples were collected during the first cycle of therapy immediately before treatment, 1 day after rituximab administration and 1 day after FC (FCR group) or 1 day after FC (FC group). The study protocol was approved by the local ethics committee (no. 495/2003 and 11/2005). The type of clinical response after 3 months allowed classifying the patients into good responders (RE) including CR or partial response (PR) or nonresponders (NR) comprising stable disease (SD) or progressive disease (PD). Overall, 9 patients had adequate responses (9 PR) and 11 patients had inadequate responses (9 SD, 2 PD). We noted some imbalances between responders and nonresponders regarding mutational status (4 vs 8 IgVH unmutated) as well as poor-risk cytogenetics (11q deletions in 1 vs 5 cases). There were four responders in the FC and five in the FCR group with more UM patients in the FC nonresponder group compared with responders (4 UM vs 1 UM). This was less pronounced for FCR patients (4 UM in nonresponders vs 3 UM in responders) suggesting that mutational status is not always directly correlated with response.
For microarray analysis, positive selection of CD19 þ cells was performed. Although this procedure guarantees high purity and comparability for all samples, potential effects of CD19 ligation on the gene expression profile of CLL cells should still be considered. Total RNA was isolated from sorted CD19 þ cells and processed for microarray analysis using human U133A GeneChips (Affymetrix, Santa Clara, CA, USA). Complete GeneChip data sets are available online as GEO entry GSE15490 http://www.ncbi.nlm.nih.gov/projects/geo/query/acc. cgi?acc ¼ GSE15490 Microarray data were filtered with an interquartile range filter. The whole data set was processed with Bioconductor (www.bioconductor.org), based on the open source platform R (www.r-project.org). Several genes related to the effect of FC and/or FCR were identified using the statistical package limma and unsupervised clustering strategy. Hierarchical clustering was performed using Pearson's correlation coefficient as distance measure and Ward's optimization criterion to cluster genes and samples. Pathway analysis was performed using DAVID bioinformatic resources (http://david.abcc.ncifcrf.gov).
To identify statistically significant changes in gene expression, we applied a widely used linear model for the assessment of differential expression. A limited number of genes showed significant changes at this early time point after treatment. These data are in accordance with the recently published report on the changes in gene expression after fludarabine therapy. 5 Because our major goal was to find an overall signature of responders and/or nonresponders, we adopted a heuristic strategy to be able to discriminate between these two groups. We first considered the genes that were 41.5-or o1.5-fold up-or downregulated in at least 60% of the responders and nonresponders after treatment. This analysis retrieved sets of genes that were up-or downregulated in the nonresponders. This includes 101 genes that have changed after FC (including PHPT1, MDM2, BAX and FDXR), 52 genes after rituximab (including S100A8, KRAS, inositol 1,4,5-trisphosphate 3-kinase (ITPKB) and CDC42) and 29 genes after FCR (including S100A8, RHOB, JUN and GPR18) (data not shown). Of note, theses genes were not always up-or downregulated in the opposite direction between the two groups. This set of genes reflects effects of therapy, but may not necessarily predict clinical response. Therefore, we next performed a more stringent analysis by considering only genes that were up-or downregulated after treatment in 460% of nonresponders and always reversibly changed in the responders. Cutoff levels of 41.14-and o0.88-fold change allowed retrieving a reasonable number of genes that could be further evaluated for their biological significance by pathway analysis. Three gene sets were identified and appeared to best discriminate between nonresponders and responders to FC, FCR or rituximab (Supplementary Tables 2,3 and 4). To be further able Table 1 Summary of patient's characteristic
Abbreviations: cycles, number of treatment cycles received; FC, fludarabine+cyclophosphamide; FCR, fludarabine, cyclophosphamide, rituximab; M, mutated IgVH; NR, nonresponder; PD, progressive disease; PR, partial response; RE, responder; SD, stable disease; UM, unmutated IgVH; 13qÀ, 13q14 deletion; 17pÀ, 17p13/P53 deletion; 11qÀ, 11qÀ22/ATM deletion; 12+, trisomy 12.
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to judge the quality of our gene set analysis, a Monte-Carlo strategy was applied. For each of the three gene sets, the correlation within the responders and nonresponders was calculated. Here, the correlation can be regarded as a measure for a consistent effect of these genes in relation to the response of the patients. One million gene sets of the same size were selected randomly and the corresponding correlation was calculated. This represents a kind of null distribution for the correlation coefficient. In at least 95% of all random samples, our gene sets performed better indicating that our gene sets are sensibly selected.
In the FC group, microarray analysis detected increased expression of 24 genes and a decrease in 21 genes in the nonresponders, which were reversibly regulated in the responders (Figure 1a; Supplementary Table 2 ). These included increased expression of ITPKB, CD44, LOC641298 (PI3-kinase (PI3-K)-related SMG1), TAF1 and BCL6 in at least four of six nonresponders, 24 h after initiation of therapy. Conversely, a decrease in CTLA4 (immune response gene) and IFI6 (apoptosis related gene) was found in at least four of six patients. In the FCR group, the effect of rituximab alone was evaluated by analyzing the changes in gene expression 24 h after initiation of therapy (before administration of FC). As shown in Figure 1b and Supplementary Table 3 , changes included upregulation of CENTD1 (Centaurin delta1: GTPase and PI3-K signaling), IL6ST (immune response, antiapoptotic, PI3-K signaling) and APRIN as well as downregulation of NDE1, CLU (clusterine), GM2A, CEACAM1 and APOBEC3G in at least four of five nonresponders. Pathway analysis revealed the involvement of the phosphatidylinositol signaling system, Toll-like receptor, B-and T-cell receptor signaling, and actin cytoskeleton regulation in response to rituximab. In this group, significant changes were also found in gene expression in the samples collected at 48 h (after the first FC infusion) compared to pre-therapy levels (Figure 1c; Supplementary Table 4 ). These included upregulation of ITGA4 (VLA-4, CD49d), ATM (ataxia telangiectasia mutated), TBRG1, GBP5, PMAIP1, EFHC1 and PTPRC in at least four of five nonresponders. Four genes (TUBG1, HIG2, EDA and KIAA1833) were upregulated upon therapy in responders. These very early changes in gene expression during the first cycle of therapy, although small in magnitude, may help in understanding the molecular events that influence the response or resistance to treatment in CLL.
To get further insight into the mechanisms leading to the beneficial effect of therapy, we focused our validation experiments on CD20 expression as immediate target of rituximab as well as the potent prosurvival pathway (PI3-K) and the surface molecules CD44 and CD49d that were increased on the RNA level in association with resistance to treatment. Microarray analysis demonstrated a transient decrease in CD20 mRNA expression 1 day after rituximab infusion in 9 of 10 FCR-treated patients (mean CD20 relative mRNA intensity before treatment: 6228 ± 4397, after rituximab 4793±4024 on day 1 and 5580±4711 on day 2). This effect was not observed in the FC group. The decrease in CD20 mRNA expression was associated with a decrease in the percentage of CD20 protein expressing CD19 þ cells (from 66.1 ± 10.3 to 27.5±6.4%) as well as the mean fluorescence intensity of CD20 on the cell surface (from 216.3 ± 39.8 to 142.8 ± 44.6), These results are in agreement with recently published data. 6 Importantly, western blotting showed a change in the total amount and the phosphorylation state of CD20 protein (Figure 2a) .
The changes in expression of PI3-K-related molecules (for example, ITPKB, LOC641298 and CENTD1) prompted us to further investigate the effect of treatment on this pathway as a paradigm for signal transduction. Reverse transcription-PCR analysis showed downregulation of AKT1, which is a downstream target of PI3-K, in the FCR, but not in the FC group (Figure 2b ). This rituximab-related effect was mainly transient in vivo. A significant downregulation of Akt1 mRNA expression and protein phosphorylation was also detected after exposure of CLL primary cells to rituximab in vitro (Figure 2c ). This suggests a mechanism of action in which engagement of rituximab with the surface molecule CD20 downregulates the prosurvival PI3-K pathway. These findings are substantiated by reported effects of rituximab on PI3-K in B-NHL cell lines. 7 Microarray analysis also revealed increased expression of CD44 (four of six nonresponders) and of CD49d/ITGA4 (four of five nonresponders) after FC and FCR, respectively (Figures 1a  and c) . These data could be also confirmed at the protein levels as shown in Figure 1d . CD44 and CD49d have been reported to be related to aggressiveness and progression of the disease in CLL. 8, 9 Therefore, we investigated whether blocking of the function of these molecules would affect CLL cell survival. Prolonged exposure of primary cells of five CLL patients to blocking antibodies against CD44 (clone IM7) or to anti-CD49d antibody (clone PS/2) was performed in cocultures with bone marrow stromal cells to minimize spontaneous apoptosis in CLL cells. 10 Results of fluorescence-activated cell sorting analysis revealed a significant induction of apoptosis in CLL cells by anti-CD44 and anti-CD49d monoclonal antibodies particularly after 5 days of incubation (Po 0.05 and 0.01 respectively; Figure 2d ). The proapoptotic effect of anti-CD49d was more pronounced compared to anti-CD44. Accordingly, CD44 and CD49d may represent additional therapeutic targets in therapy-resistant CLL cases.
Taken together, this study, although on a relatively small cohort of CLL cases, represents 'proof of principle' and shows the feasibility of linking clinical outcome to sGEP of CLL cells obtained early during treatment with the current standard regimens FC and FCR. One shortcoming of the study is that changes in GEP were subtle and not as strong as usually considered significant. This may be due to the short intervals of analysis (24-48 h) as has been also recently reported. 5 Although changes were not always statistically significant, they led to the discovery of biologically important genes and pathways and were confirmed by protein expression analysis. Importantly, we were able to validate functionally genes like CD49d, CD44, CD20 and Akt, which are closely related to the pathology of CLL. [6] [7] [8] [9] However, consolidation studies on a larger number of patients are needed and ongoing.
The sequential assessment of GEP supported with protein expression before and after therapy could reflect functional changes in CLL cells as a response to treatment. sGEP thus represents a tool to guide therapy early during the first cycle of treatment in CLL. The study revealed the involvement of genes related to PI3-K signaling (for example, ITPKB, CENTD1) and cell adhesion (CD44 and CD49d) in resistance to therapy. The PI3-K/Akt pathway was shown to be regulated downstream of CD20 signaling. Furthermore, our data confirm that CD20 is transiently downregulated after rituximab therapy and showed its regulation at the protein level and post-translational level by de-phosphorylation. This finding may have consequences on scheduling of CD20 antibody therapy. Finally, we provide a set of genes that can help to predict response or resistance to therapy and identify potential targets to overcome resistance.
